Get the Stockscreener App
11.58
6.16%
-0.76
After Hours:
11.52
-0.06
-0.52%
Kalvista Pharmaceuticals Inc stock is traded at $11.58, with a volume of 692.68K.
It is down -6.16% in the last 24 hours and down -13.52% over the past month.
See More
Previous Close:
$12.34
Open:
$12.24
24h Volume:
692.68K
Relative Volume:
1.79
Market Cap:
$453.33M
Revenue:
-
Net Income/Loss:
$-108.30M
P/E Ratio:
-3.6646
EPS:
-3.16
Net Cash Flow:
$-97.15M
1W Performance:
+18.40%
1M Performance:
-13.52%
6M Performance:
-2.36%
1Y Performance:
+20.25%
1-Day Range:
$11.44
$12.55
1-Week Range:
$9.451
$12.55
52-Week Range:
$7.21
$16.88
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
H.C. Wainwright initates KalVista Pharmaceuticals Inc (KALV) rating to a Buy - Knox Daily
KalVista Pharmaceuticals Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema - The Bakersfield Californian
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema - StockTitan
Jones Trading Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation - MSN
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Up to $10.00 - MarketBeat
Jones Trading Sets $35 Target on Kalvista Pharmaceuticals - Investing.com
KalVista Completes Study On Hereditary Disorder Treatment: Shares Dip - BW Healthcare
KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF) - StockTitan
Kaival Brands’ (KAVL) Stock Surges After Merger Announcement with Delta Corp. - TipRanks
(KALA) Long Term Investment Analysis - Stock Traders Daily
Kaival Brands Innovations Group Inc. (NASDAQ:KAVL) Stock Makes a Big Move: But Why? - DRP Journal
Great Point Partners LLC Takes $15.77 Million Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
KLAC (KLA Corp.) may reap gains as insiders became active recently - Knox Daily
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements - Barchart
Kaival Brands Shares More Than Double on Delta Corp Holdings Merger - MarketWatch
Head-To-Head Review: KalVista Pharmaceuticals (NASDAQ:KALV) vs. Mersana Therapeutics (NASDAQ:MRSN) - Defense World
KAVL’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
What's Going On With Kaival Brands Stock Monday? - Benzinga
Tairen Capital Ltd Trims Stock Position in KLA Co. (NASDAQ:KLAC) - MarketBeat
An analyst sees good growth prospects for Kaltura Inc (KLTR) - SETE News
Edge Capital Group LLC Has $6.13 Million Stock Position in KLA Co. (NASDAQ:KLAC) - Defense World
Calithera Biosciences (NASDAQ:CALA) Coverage Initiated by Analysts at StockNews.com - Defense World
Texas Permanent School Fund Corp Purchases 2,319 Shares of Kaiser Aluminum Co. (NASDAQ:KALU) - Defense World
(KALV) Long Term Investment Analysis - Stock Traders Daily
Stocks Flashing Renewed Technical Strength: KLA - Investor's Business Daily
KLAC Shares Experience Decline in Value - Knox Daily
Novo Nordisk and NanoVation Inked $600M+ Genetic Medicine Deal - Inside Precision Medicine
Closing Figures Unveiled: KLA Corp. (KLAC) Drop -1.16, Closes at 731.04 - The Dwinnex
Did KLA Corp. (KLAC) perform well in the last session? - US Post News
Bank of New York Mellon Corp Purchases 23,547 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
The Potential Rise in the Price of KalVista Pharmaceuticals Inc (KALV) following insiders activity - Knox Daily
Kaiser Aluminum Co. (NASDAQ:KALU) Short Interest Down 14.6% in August - Defense World
Trading Day Triumph: KalVista Pharmaceuticals Inc (KALV) Ends at 10.57, a -1.86 Surge/Plunge - The Dwinnex
Why KLA (KLAC) Outpaced the Stock Market Today - Yahoo Finance
KLAC stock rated a Hold by TD Cowen - Knox Daily
ANEW Medical announces name change to Klotho Neurosciences - TipRanks
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc. - GlobeNewswire
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc. - Yahoo Finance
KLA Co. (NASDAQ:KLAC) Shares Bought by Edgestream Partners L.P. - MarketBeat
Kairos Pharma opens at $4, IPO priced at $4 By Investing.com - Investing.com Australia
First Turn Management LLC Sells 119,880 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
Examining KalVista Pharmaceuticals Inc (KALV) stock is warranted - US Post News
KALV Stock Sees Decline of Approximately -18.73% in Last Five Days - Knox Daily
Metric Analysis: KalVista Pharmaceuticals Inc (KALV)’s Key Ratios in the Limelight - The Dwinnex
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Closing Figures Unveiled: KalVista Pharmaceuticals Inc (KALV) Drop -5.56, Closes at 11.21 - The Dwinnex
KalVista Pharmaceuticals Inc (KALV) Stock: A Year of Stock Market Dynamics - The InvestChronicle
KalVista Pharmaceuticals appoints new CFO - Investing.com
KalVista Pharmaceuticals CEO sells shares worth over $89k - Investing.com India
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $89,620.88 in Stock - MarketBeat
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):